{"id":1135,"date":"2022-04-13T14:58:32","date_gmt":"2022-04-13T05:58:32","guid":{"rendered":"https:\/\/www.gotoku.co.jp\/wordpress\/?page_id=1135"},"modified":"2025-05-27T11:25:30","modified_gmt":"2025-05-27T02:25:30","slug":"history","status":"publish","type":"page","link":"https:\/\/www.gotoku.co.jp\/en\/history\/","title":{"rendered":"History"},"content":{"rendered":"\n

History<\/h2>\n\n\n\n
1949<\/strong><\/td>Shoichi Nakayama (Founder) established Gotoku Chemical Promotion Partnership Corporation for the purpose of the distribution of chemicals,food additives and the like.<\/td><\/tr>
1950<\/strong><\/td>Launched CMC-Na (Carboxymethyl cellulose Sodium, also known as Cellulose Glycolate) under the trade name of T.P.T-\u32e9\u00ae<\/sup> (Trademark creator, Shoichi Nakayama), based on the license of the Agency of Industrial Science and Technology (of those days).<\/td><\/tr>
1961<\/strong><\/td>Playing a central role, Gotoku Chemical researched and developed Disintegrant, CMC-Ca (Official name for the food additive = Calcium Cellulose Glycolate) to be successful in commercialization.
Brought it to market under the trade name of E.C.G-505\u00ae<\/sup> (Trade name creator, Shoichi Nakayama) and launched market cultivation as the exclusive distributor to extend sales activities nationwide.<\/td><\/tr>
1963<\/strong><\/td>CMC-Ca (Calcium Cellulose Glycolate) was listed in the Japan's Specifications and Standards for Food Additives (The 4th edition) and approved as a food additive. Launched E.C.G-FA\u00ae<\/sup> as a food additive.
(Gotoku Chemical = Exclusive distributor)<\/td><\/tr>
1966<\/strong><\/td>E.C.G-505\u00ae<\/sup> (JP official name, Carmellose Calcium) was listed in the Japanese Pharmacopoeia (JP) 7th edition (the second part). Approved as one of JP drugs.<\/td><\/tr>
1967<\/strong><\/td>Originally researched and developed Disintegrant, CMC-H (Acid-type carboxymethylcellulose) to accomplish commercialization. Brought it to market under the trade name of NS-300\u00ae<\/sup> (Trade name creator, Shoichi Nakayama).
Advanced market cultivation as the exclusive distributor of NS-300\u00ae<\/sup> with the goal of nationwide sales.<\/td><\/tr>
1985<\/strong><\/td>Founder, Shoichi Nakayama acceded to Representative Partner & Chairman. Yukihiro Nakayama was designated as Representative Partner & President (after Accounting Manager, Sales Manager and Vice-President).
E.C.G-505\u00ae<\/sup> was listed in USP-NF, having a high international valuation.<\/td><\/tr>
1986<\/strong><\/td>NS-300\u00ae<\/sup> (JP official name = Carmellose) was listed in the Japanese Pharmacopoeia (11th edition).
Approved as one of JP drugs.<\/td><\/tr>
1989<\/strong><\/td>At the time of the 40th anniversary of the foundation, Partnership was reorganized into Company Limited.
Gotoku Chemical Co.,Ltd. newly started. Yukihiro Nakayama acceded to Representative Director & President.<\/td><\/tr>
1991<\/strong><\/td>E.C.G-505\u00ae<\/sup> was elected to one of the pharmaceutical excipients of Japan. U.S.A and Europe,
\"ICH Harmonization Monographs\" (25 items used very often in the world).<\/td><\/tr>
1993<\/strong><\/td>The performance of E.C.G-505\u00ae<\/sup> was recognized in Europe and E.C.G-505\u00ae<\/sup> was listed in European Pharmacopoeia (EP).<\/td><\/tr>
1996<\/strong><\/td>Highly evaluated abroad, NS-300\u00ae<\/sup> was listed in \"the Addendum of ICH Harmonization monographs\".<\/td><\/tr>
2006<\/strong><\/td>NS-300\u00ae<\/sup> was registered in DMF (Drug Master File). *Registration No.19767<\/td><\/tr>
2010<\/strong><\/td>Highly evaluated across the world, NS-300\u00ae<\/sup> was listed in USP-NF and EP.<\/td><\/tr>
2015<\/strong><\/td>The performance of E.C.G-505\u00ae<\/sup> was approved and listed in ChP.<\/td><\/tr>
2016<\/strong><\/td>E.C.G-505\u00ae<\/sup> was registered in DMF (Drug Master File). *Registration No.030379<\/td><\/tr>
2019<\/strong><\/td>E.C.G-505\u00ae<\/sup> was registered in Chinese DMF (Drug Master File) <\/td>*Registration No.F20180001742<\/td><\/tr>
NS-300\u00ae<\/sup> was registered in Chinese DMF (Drug Master File)<\/td>*Registration No.F20180001743<\/td><\/tr>
Opened a liaison office in London \/ the United Kingdom.<\/td><\/tr>
<\/td>Note: USP=United States Pharmacopoeia, NF=National Formulary, EP=European Pharmacopoeia
\u3000\u3000\u3000ChP=Chinese Pharmacopoeia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

History<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","ub_ctt_via":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_locale":"en_US","_original_post":"https:\/\/www.gotoku.co.jp\/wordpress\/?page_id=68","vkexunit_cta_each_option":"","footnotes":""},"class_list":["post-1135","page","type-page","status-publish","hentry","en-US"],"aioseo_notices":[],"featured_image_src":null,"_links":{"self":[{"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/pages\/1135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/comments?post=1135"}],"version-history":[{"count":29,"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/pages\/1135\/revisions"}],"predecessor-version":[{"id":3218,"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/pages\/1135\/revisions\/3218"}],"wp:attachment":[{"href":"https:\/\/www.gotoku.co.jp\/wp-json\/wp\/v2\/media?parent=1135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}